These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Myopathy during treatment with fibrates and lovastatin]. Jensen K Ugeskr Laeger; 1991 Mar; 153(12):862. PubMed ID: 2014580 [No Abstract] [Full Text] [Related]
3. Penicillamine induced polymyositis and dermatomyositis. Carroll GJ; Will RK; Peter JB; Garlepp MJ; Dawkins RL J Rheumatol; 1987 Oct; 14(5):995-1001. PubMed ID: 3501473 [TBL] [Abstract][Full Text] [Related]
4. Gemfibrozil induced myositis: a case report with light microscopic and ultrastructural study. Chow LT; Chow WH Chin Med Sci J; 1994 Jun; 9(2):129-31. PubMed ID: 8000060 [TBL] [Abstract][Full Text] [Related]
5. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Goldman JA; Fishman AB; Lee JE; Johnson RJ Arthritis Rheum; 1989 Mar; 32(3):358-9. PubMed ID: 2930608 [No Abstract] [Full Text] [Related]
6. Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis. Chow LT; Chow WH Med J Aust; 1993 Jan; 158(1):48-9. PubMed ID: 8417294 [TBL] [Abstract][Full Text] [Related]
7. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. András C; Ponyi A; Constantin T; Csiki Z; Szekanecz E; Szodoray P; Dankó K J Rheumatol; 2008 Mar; 35(3):438-44. PubMed ID: 18203322 [TBL] [Abstract][Full Text] [Related]
8. The relationship of dermatomyositis and polymyositis to internal malignancy. Callen JP; Hyla JF; Bole GG; Kay DR Arch Dermatol; 1980 Mar; 116(3):295-8. PubMed ID: 7369745 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Arahata K; Engel AG Ann Neurol; 1984 Aug; 16(2):193-208. PubMed ID: 6383191 [TBL] [Abstract][Full Text] [Related]
10. [Spectrum of antinuclear and anti-cytoplasmic antibodies in dermatomyositis and polymyositis overlap syndromes]. Meurer M; Hausmann-Martinez-Pardo G; Braun-Falco O Hautarzt; 1989 Oct; 40(10):623-9. PubMed ID: 2482267 [TBL] [Abstract][Full Text] [Related]
11. Inclusion body myositis: clinical and pathological boundaries. Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577 [TBL] [Abstract][Full Text] [Related]
15. [Myositis associated with tumors]. András C; Ponyi A; Constantin T; Csiki Z; Illés A; Szegedi G; Dankó K Magy Onkol; 2002; 46(3):253-9. PubMed ID: 12368921 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis). Pongratz D J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756 [TBL] [Abstract][Full Text] [Related]
17. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis. Callen JP Rheum Dis Clin North Am; 1994 Nov; 20(4):943-53. PubMed ID: 7855330 [TBL] [Abstract][Full Text] [Related]
18. Clinical spectrum of inflammatory myositis in South India--a ten year study. Porkodi R; Shanmuganandan K; Parthiban M; Madhavan R; Rajendran P J Assoc Physicians India; 2002 Oct; 50():1255-8. PubMed ID: 12568209 [TBL] [Abstract][Full Text] [Related]
19. [Histopathologic aspects of polymyositis and dermatomyositis. Correlation with the clinical course. Study of 57 cases]. Gayraud M; Tome F; Herson S; Chevallay M; Fardeau M; Godeau P Ann Med Interne (Paris); 1989; 140(6):445-8. PubMed ID: 2696397 [TBL] [Abstract][Full Text] [Related]
20. [The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis']. Hoogendijk JE; Bijlsma JW; van Engelen BG; Lindeman E; van Royen-Kerkhof A; de Rie MA; de Visser M; Jennekens FG; Ned Tijdschr Geneeskd; 2005 Sep; 149(38):2104-11. PubMed ID: 16201600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]